Switzerland-based Relief Therapeutics Holding AG (SIX: RLF)(OTCQB: RLFTF), and NeuroRx Inc, a clinical stage, small molecule pharmaceutical company, have established supply chain contracts and ordered sufficient drug substance (RLF-100TM) in order to treat one million patients with COVID-19, if the pandemic continues, it was reported on Wednesday.

Presently, the product is in FDA-approved phase 2b/3 clinical trials intended for the treatment of critical COVID-19 in the United States. The product's European trials are in preparation and are scheduled to commence in the first quarter of 2021.

Both firms have chosen Nephron Pharmaceuticals Inc to produce commercial supplies of RLF-100 so that adequate drug inventory will be immediately available, if the clinical trials showcase safety and efficacy. They have also contracted Bachem Americas to produce RLF-100TM drug substance intended to treat one million patients. They have also chosen a leading nationwide pharmaceutical logistics partner to ensure overnight supply to US hospitals, if the product continue to succeed in clinical trials.